Cardio Diagnostics Valuation
| CDIO Stock | USD 1.51 0.09 5.63% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Cardio Diagnostics shows a prevailing Real Value of $1.45 per share. The current price of the firm is $1.51. Our model approximates the value of Cardio Diagnostics from analyzing the firm fundamentals such as Return On Equity of -1.11, operating margin of (599.51) %, and Shares Outstanding of 1.83 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cardio Diagnostics' valuation include:
Price Book 0.3573 | Enterprise Value | Enterprise Value Ebitda (22.48) | Price Sales 174.7141 | Enterprise Value Revenue 3.7541 |
Overvalued
Today
Please note that Cardio Diagnostics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Cardio Diagnostics is based on 3 months time horizon. Increasing Cardio Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cardio Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cardio Stock. However, Cardio Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.51 | Real 1.45 | Target 60.0 | Hype 1.5 | Naive 1.97 |
The intrinsic value of Cardio Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cardio Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cardio Diagnostics Holdings helps investors to forecast how Cardio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cardio Diagnostics more accurately as focusing exclusively on Cardio Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cardio Diagnostics' intrinsic value based on its ongoing forecasts of Cardio Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cardio Diagnostics' closest peers.
Cardio Diagnostics Cash |
|
Cardio Diagnostics Total Value Analysis
Cardio Diagnostics Holdings is currently forecasted to have valuation of (2.96 M) with market capitalization of 2.76 M, debt of 969.86 K, and cash on hands of 9.66 M. The negative valuation of Cardio Diagnostics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Cardio Diagnostics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.96 M) | 2.76 M | 969.86 K | 9.66 M |
Cardio Diagnostics Investor Information
The company has price-to-book (P/B) ratio of 0.36. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardio Diagnostics recorded a loss per share of 11.91. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 13th of May 2025. Based on the key indicators related to Cardio Diagnostics' liquidity, profitability, solvency, and operating efficiency, Cardio Diagnostics Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Cardio Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cardio Diagnostics has an asset utilization ratio of 0.33 percent. This suggests that the Company is making $0.003287 for each dollar of assets. An increasing asset utilization means that Cardio Diagnostics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.Cardio Diagnostics Profitability Analysis
Based on Cardio Diagnostics' profitability indicators, Cardio Diagnostics Holdings may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Cardio Diagnostics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2010-12-31 | Previous Quarter -7.5 M | Current Value -7.2 M | Quarterly Volatility 3.2 M |
For Cardio Diagnostics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cardio Diagnostics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cardio Diagnostics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cardio Diagnostics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cardio Diagnostics over time as well as its relative position and ranking within its peers.
Cardio Diagnostics Earnings per Share Projection vs Actual
By analyzing Cardio Diagnostics' earnings estimates, investors can diagnose different trends across Cardio Diagnostics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Cardio Diagnostics Holdings is based on EPS before non-recurring items and includes expenses related to employee stock options.Cardio Diagnostics Ownership Allocation
Cardio Diagnostics Holdings shows 6.79 percent of its outstanding shares held by insiders and 6.34 percent owned by other corporate entities.Cardio Diagnostics Profitability Analysis
The company reported the previous year's revenue of 34.89 K. Net Loss for the year was (8.38 M) with profit before overhead, payroll, taxes, and interest of 15.78 K.About Cardio Diagnostics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Cardio Diagnostics Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cardio Diagnostics based exclusively on its fundamental and basic technical indicators. By analyzing Cardio Diagnostics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Cardio Diagnostics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cardio Diagnostics. We calculate exposure to Cardio Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cardio Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 40.1 K | 42.1 K | |
| Pretax Profit Margin | (216.25) | (227.07) | |
| Operating Profit Margin | (215.80) | (226.59) | |
| Net Loss | (216.25) | (227.07) |
Cardio Diagnostics Current Valuation Indicators
Cardio Diagnostics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Cardio Diagnostics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cardio Diagnostics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cardio Diagnostics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cardio Diagnostics' worth.When determining whether Cardio Diagnostics is a strong investment it is important to analyze Cardio Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardio Diagnostics' future performance. For an informed investment choice regarding Cardio Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardio Diagnostics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (11.91) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets | Return On Equity |
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.